Eyenovia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 10, 2022 at 04:55 pm EDT
Share
Eyenovia, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 7.24 million compared to USD 4.84 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.19 a year ago.
For the six months, net loss was USD 14.58 million compared to USD 10.19 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 0.4 a year ago.
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.